The Food and Drug Administration has cleared Novavax to move forward with testing of a combination vaccine for COVID-19 and ...

The U.S. Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines, the company said on Monday.

Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, ...

Novavax said the Food and Drug Administration allowed it to continue testing a combination COVID-19-flu and standalone flu vaccine that had been put on hold.

(RTTNews) - Novavax, Inc. (NVAX) Monday said the Food and Drug Administration or FDA has removed the clinical hold on its COVID-19-Influenza Combination (CIC) and stand-alone influenza vaccine ...

Novavax (NASDAQ:NVAX) shares climbed 12% premarket on Monday after the U.S. FDA lifted clinical hold on the investigational new drug application for the pharma firm’s COVID-19-Influenza Combination ...

Novavax will be working with the clinical trial investigators and other partners to resume trial activities as quickly as possible. Also Read: DeSantis Administration Cautions Against Pfizer, Moderna ...

Novavax ( (NVAX) ) has issued an announcement. Novavax, Inc. and the UK Health Security Agency have reached a settlement to terminate their ...

Novavax has inked another settlement for a past COVID-19 vaccine supply deal. The Maryland biotech has agreed to pay $123.8 million to end a COVID vaccine supply pact with the UK Health Security ...

The U.S. Food and Drug Administration (FDA) has lifted its hold on a late-stage trial for Novavax’s COVID-influenza combination and standalone flu vaccines, the company reported on Monday (NASDAQ:MNDY ...

Novavax (NVAX.O), opens new tab said on Tuesday that it has entered into a termination and settlement agreement with the UK Health Security Agency (UKHSA) related to its COVID-19 vaccine supply ...